Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
The National Eye Institute reported today that current treatments for a common, sight-threatening complication of diabetes have proved 95 percent effective in maintaining vision, but 8,000 still go blind each year from this disease.
Researchers report that donor-recipient tissue typing had no significant long-term effect on the success of corneal transplantation in a nationwide clinical study of over 400 patients at high risk for rejection.
Although commonly used, oral corticosteroids alone are ineffective in treating optic neuritis, a debilitating inflammation of the optic nerve, and actually increase a person’s risk for future attacks.
Results from two years of patient followup in a randomized clinical trial suggest that argon laser therapy may be a safe and effective alternative to eyedrops as a first treatment for patients with newly diagnosed open-angle glaucoma.
Louis W. Sullivan, Secretary of Health and Human Services, has announced results of a clinical trial demonstrating a 50 percent improvement in surgical control of glaucoma in patients at high risk for blindness.
New findings from a nationwide clinical trial supported by theNational Eye Institute (NEI) provide further evidence that laser treatment is highly effective in preventing visual loss from diabetic eye disease.
Briefly freezing a portion of the eye’s surface can protect many premature infants against blindness from retinopathy of prematurity (ROP), a disease that causes visual loss in 2,600 infants in the United States annually.
New evidence from a nationwide study shows that treatment for some powerful beams of light can substantially reduce the risk of blindness for some people with severe eye disease caused by diabetes.